Related Experiment Video

Updated: Jun 13, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development

Debashis Sarker1, Simon Pacey, Paul Workman

  • 1Signal Transduction & Molecular Pharmacology Team, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, SM2 5NG, UK.

Biomarkers in Medicine
|May 19, 2010
PubMed

Insights

Biomarker data is crucial for advancing oncology drug development. Implementing pharmacokinetic and pharmacodynamic biomarkers in clinical trials ensures the full potential of novel cancer drugs is realized.

Area of Science:

  • Oncology
  • Pharmacology
  • Biomarker Research

Background:

  • Drug development in oncology faces challenges keeping pace with molecular target discovery.
  • Current drug development frameworks may not adequately assess novel targeted agents.
  • Understanding drug effects on targets is essential for rational drug development.

Purpose of the Study:

  • To discuss the impact of biomarker data on oncology drug development.
  • To highlight the role of pharmacokinetic and pharmacodynamic biomarkers.
  • To advocate for the use of fit-for-purpose biomarkers in clinical trials.

Main Methods:

  • Review of current practices in oncology drug development.
  • Discussion of biomarker investigation, development, validation, and use.
  • Examination of pharmacokinetic and pharmacodynamic biomarker applications.
  • Consideration of regulatory assay challenges.

Main Results:

  • Biomarker data can significantly impact drug development strategies.
  • Pharmacokinetic and pharmacodynamic biomarkers are vital for clinical translation.
  • Existing cytotoxic agent frameworks may limit the assessment of targeted therapies.

Conclusions:

  • Biomarker investigation is essential for the rational development of novel cancer drugs.
  • Pharmacokinetic and pharmacodynamic biomarkers should be integrated into clinical trials.
  • Implementing appropriate biomarkers will help realize the full potential of new oncology agents.
  • Addressing regulatory challenges for biomarker assays is critical.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect01:26

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...